Activation of platelets by autogenous vein grafts is not prevented by acetylsalicylic acid and dipyridamole.
We have shown previously that experimental autogenous vein grafts activate platelets for up to four months following operation. In the present study, animals were treated with middle dose ASA (10 mg X kg-1 X 24 h-1) plus dipyridamole (8 mg X kg-1 X 24 h-1) and followed for 8 months. Despite this treatment, platelets were activated by the vein graft for up to four months after operation but not after this time. Similarly, treatment with low dose ASA (0.5 mg X kg-1 X 24 h-1) plus dipyridamole (8 mg X kg-1 X 25 h-1), high dose ASA (40 mg X kg-1 X 24 h-1) plus dipyridamole (8 mg X kg-1 X 24 h-1), or dipyridamole alone (8 mg X kg-1 X 24 h-1), did not prevent the vein graft-induced activation of platelets. Full inhibition of platelet arachidonic acid metabolism was demonstrated in the high dose ASA plus dipyridamole group. These results suggest that the interaction between the vessel wall and platelet is not inhibited by ASA plus dipyridamole. Platelets have first to be activated before causing intimal hyperplasia. Since aspirin and dipyridamole did not prevent activation of platelets by the graft, this drug combination is unlikely to prevent the development of intimal hyperplasia in the graft wall.
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000818:Animals; D001095:Arachidonic Acids / Q000494:pharmacology; D001241:Aspirin / Q000008:administration & dosage / Q000494:pharmacology*; D004176:Dipyridamole / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D007601:Jugular Veins / Q000637:transplantation*; D010974:Platelet Aggregation / Q000187:drug effects*; D011817:Rabbits; D013997:Time Factors
D001095:Arachidonic Acids; D000244:Adenosine Diphosphate; D004176:Dipyridamole; D001241:Aspirin